REPLIGEN CORP Goodwill
REPLIGEN CORP (RGEN) had Goodwill of $1.10 billion as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:Goodwill · last filed 2026-07-29
- 2026-06-30: Goodwill $1.10B.
- 2026-03-31: Goodwill $1.11B.
- 2025-12-31: Goodwill $1.11B.
- 2025-09-30: Goodwill $1.11B.
| Period end | Goodwill | Goodwill as first filed |
|---|---|---|
| 2026-06-30 | $1.10B 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $1.11B 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $1.11B 10-Q · filed 2026-07-29 | |
| 2025-09-30 | $1.11B 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $1.11B 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $1.08B 10-Q · filed 2025-08-07 | |
| 2024-12-31 | $1.03B 10-K · filed 2026-02-26 | |
| 2024-09-30 | $987.62M 10-Q · filed 2024-11-18 | |
| 2024-06-30 | $985.61M 10-Q/A · filed 2024-11-18 | |
| 2024-03-31 | $985.96M 10-Q/A · filed 2024-11-18 | |
| 2023-12-31 | $987.12M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $869.25M 10-Q/A · filed 2024-11-18 | |
| 2023-06-30 | $870.69M 10-Q/A · filed 2024-11-18 | |
| 2023-03-31 | $856.30M 10-Q/A · filed 2024-11-18 | |
| 2022-12-31 | $855.51M 10-K · filed 2025-03-14 | |
| 2022-09-30 | $851.41M 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $854.33M 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $859.49M 10-Q · filed 2022-04-27 | |
| 2021-12-31 | $860.36M 10-K/A · filed 2024-11-18 | |
| 2021-09-30 | $833.56M 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $617.59M 10-Q · filed 2021-07-27 | |
| 2021-03-31 | $617.52M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $618.30M 10-K · filed 2023-02-22 | |
| 2020-09-30 | $482.04M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $468.73M 10-Q · filed 2020-07-30 | |
| 2020-03-31 | $468.38M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $468.41M 10-K · filed 2022-02-17 | |
| 2019-09-30 | $468.85M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $469.51M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $326.39M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $326.74M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $326.98M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $327.10M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $327.99M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $327.33M 10-K · filed 2020-02-26 | |
| 2017-09-30 | $326.65M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $60.98M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $59.78M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $59.55M 10-K · filed 2019-03-01 | |
| 2016-09-30 | $31.16M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $31.03M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $14.35M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $14.35M 10-K · filed 2017-02-23 | |
| 2015-09-30 | $14.35M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $14.35M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $14.31M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $14.19M 10-K · filed 2016-02-25 | $14.18M 10-K · filed 2015-03-17 |
| 2014-09-30 | $14.14M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $14.17M 10-Q · filed 2014-08-11 | |
| 2014-06-02 | $13.35M 10-K · filed 2016-02-25 | $13.19M 10-K · filed 2015-03-17 |
| 2014-03-31 | $994.00K 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $994.00K 10-K · filed 2015-03-17 | |
| 2013-09-30 | $994.00K 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $994.00K 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $994.00K 10-Q · filed 2013-05-07 | |
| 2012-12-31 | $994.00K 10-K · filed 2014-03-14 | |
| 2012-09-30 | $994.00K 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $994.00K 10-Q · filed 2012-08-09 | |
| 2012-03-31 | $994.00K 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $994.00K 10-K · filed 2013-03-15 | |
| 2011-09-30 | $994.00K 10-Q · filed 2011-11-09 | |
| 2011-06-30 | $994.00K 10-Q · filed 2011-08-05 | |
| 2011-03-31 | $994.00K 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |